The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR(PDF, 524KB) and Technical Notes(PDF, 752KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 28.13
Age-Specific Ratesa and Counts for the Top 5 Cancer Sitesb by Single Year of Age at Diagnosis
SEER Cancer Incidencec 2011-2015
Age at Diagnosis | Primary Site | Rate | Number of Cases |
---|---|---|---|
Age <1 | All Sites | 23.6 | 1,335 |
Leukemia | 4.7 | 265 | |
Acute Lymphocytic Leukemia | 2.1 | 116 | |
Brain and ONSd | 3.6 | 205 | |
Soft Tissue | 3.5 | 199 | |
Eye and Orbit | 3.3 | 189 | |
Other Endocrine | 2.7 | 152 | |
Age 1 | All Sites | 21.9 | 1,242 |
Leukemia | 6.8 | 383 | |
Acute Lymphocytic Leukemia | 4.4 | 249 | |
Brain and ONSd | 4.5 | 254 | |
Kidney and Renal Pelvis | 2.0 | 115 | |
Eye and Orbit | 1.8 | 100 | |
Soft Tissue | 1.7 | 96 | |
Age 2 | All Sites | 24.1 | 1,370 |
Leukemia | 10.3 | 586 | |
Acute Lymphocytic Leukemia | 9.1 | 519 | |
Brain and ONSd | 4.7 | 267 | |
Kidney and Renal Pelvis | 2.2 | 127 | |
Soft Tissue | 1.5 | 84 | |
Other Endocrine | 1.4 | 79 | |
Age 3 | All Sites | 23.0 | 1,319 |
Leukemia | 11.2 | 643 | |
Acute Lymphocytic Leukemia | 10.1 | 583 | |
Brain and ONSd | 3.8 | 219 | |
Kidney and Renal Pelvis | 2.2 | 127 | |
Soft Tissue | 1.1 | 61 | |
Other Endocrine | 1.0 | 59 | |
Age 4 | All Sites | 18.6 | 1,080 |
Leukemia | 8.5 | 493 | |
Acute Lymphocytic Leukemia | 7.4 | 432 | |
Brain and ONSd | 3.7 | 215 | |
Kidney and Renal Pelvis | 1.5 | 87 | |
Non-Hodgkin Lymphoma | 1.1 | 63 | |
Soft Tissue | 0.9 | 55 | |
Age 5 | All Sites | 14.9 | 867 |
Leukemia | 5.9 | 346 | |
Acute Lymphocytic Leukemia | 5.0 | 294 | |
Brain and ONSd | 3.7 | 213 | |
Kidney and Renal Pelvis | 1.2 | 70 | |
Non-Hodgkin Lymphoma | 1.1 | 64 | |
Soft Tissue | 0.7 | 40 | |
Age 6 | All Sites | 14.1 | 824 |
Leukemia | 5.0 | 292 | |
Acute Lymphocytic Leukemia | 4.4 | 260 | |
Brain and ONSd | 3.9 | 231 | |
Non-Hodgkin Lymphoma | 1.2 | 71 | |
Kidney and Renal Pelvis | 0.8 | 48 | |
Soft Tissue | 0.6 | 38 | |
Age 7 | All Sites | 12.2 | 718 |
Leukemia | 3.8 | 221 | |
Acute Lymphocytic Leukemia | 3.2 | 189 | |
Brain and ONSd | 3.5 | 204 | |
Non-Hodgkin Lymphoma | 1.2 | 73 | |
Soft Tissue | 0.8 | 46 | |
Bones and Joints | 0.6 | 34 | |
Age 8 | All Sites | 11.0 | 641 |
Leukemia | 3.5 | 202 | |
Acute Lymphocytic Leukemia | 2.9 | 168 | |
Brain and ONSd | 3.0 | 173 | |
Non-Hodgkin Lymphoma | 1.1 | 64 | |
Bones and Joints | 0.7 | 40 | |
Soft Tissue | 0.6 | 34 | |
Age 9 | All Sites | 12.3 | 718 |
Leukemia | 3.6 | 207 | |
Acute Lymphocytic Leukemia | 2.7 | 158 | |
Brain and ONSd | 3.2 | 185 | |
Non-Hodgkin Lymphoma | 1.4 | 80 | |
Bones and Joints | 1.1 | 65 | |
Hodgkin Lymphoma | 0.7 | 38 | |
Age 10 | All Sites | 11.9 | 695 |
Brain and ONSd | 2.9 | 171 | |
Leukemia | 2.8 | 161 | |
Acute Lymphocytic Leukemia | 2.2 | 129 | |
Non-Hodgkin Lymphoma | 1.3 | 76 | |
Bones and Joints | 1.1 | 62 | |
Soft Tissue | 0.8 | 46 | |
Age 11 | All Sites | 12.2 | 715 |
Leukemia | 2.8 | 163 | |
Acute Lymphocytic Leukemia | 1.9 | 110 | |
Brain and ONSd | 2.6 | 154 | |
Bones and Joints | 1.5 | 86 | |
Non-Hodgkin Lymphoma | 1.0 | 61 | |
Hodgkin Lymphoma | 0.9 | 50 | |
Age 12 | All Sites | 15.1 | 885 |
Leukemia | 3.9 | 227 | |
Acute Lymphocytic Leukemia | 2.7 | 161 | |
Brain and ONSd | 2.5 | 147 | |
Bones and Joints | 1.8 | 105 | |
Non-Hodgkin Lymphoma | 1.3 | 75 | |
Hodgkin Lymphoma | 1.2 | 71 | |
Age 13 | All Sites | 15.7 | 921 |
Leukemia | 3.2 | 186 | |
Acute Lymphocytic Leukemia | 2.1 | 124 | |
Brain and ONSd | 2.6 | 155 | |
Bones and Joints | 1.8 | 105 | |
Non-Hodgkin Lymphoma | 1.6 | 97 | |
Hodgkin Lymphoma | 1.3 | 78 | |
Age 14 | All Sites | 17.3 | 1,028 |
Leukemia | 3.9 | 229 | |
Acute Lymphocytic Leukemia | 2.5 | 148 | |
Brain and ONSd | 2.6 | 152 | |
Thyroid | 1.7 | 103 | |
Non-Hodgkin Lymphoma | 1.7 | 100 | |
Hodgkin Lymphoma | 1.6 | 96 | |
Age 15 | All Sites | 20.0 | 1,192 |
Leukemia | 3.6 | 212 | |
Acute Lymphocytic Leukemia | 2.3 | 138 | |
Brain and ONSd | 2.5 | 150 | |
Hodgkin Lymphoma | 2.2 | 128 | |
Bones and Joints | 2.0 | 118 | |
Non-Hodgkin Lymphoma | 1.9 | 116 | |
Age 16 | All Sites | 20.2 | 1,208 |
Leukemia | 3.2 | 190 | |
Acute Lymphocytic Leukemia | 1.9 | 116 | |
Brain and ONSd | 2.8 | 169 | |
Thyroid | 2.3 | 139 | |
Hodgkin Lymphoma | 2.3 | 139 | |
Non-Hodgkin Lymphoma | 1.8 | 110 | |
Age 17 | All Sites | 23.7 | 1,437 |
Leukemia | 3.5 | 210 | |
Acute Lymphocytic Leukemia | 1.8 | 112 | |
Hodgkin Lymphoma | 3.2 | 193 | |
Thyroid | 3.0 | 182 | |
Brain and ONSd | 2.4 | 148 | |
Non-Hodgkin Lymphoma | 2.1 | 129 | |
Age 18 | All Sites | 24.9 | 1,509 |
Thyroid | 3.7 | 227 | |
Hodgkin Lymphoma | 3.4 | 207 | |
Testise | 3.0 | 180 | |
Leukemia | 2.9 | 177 | |
Acute Lymphocytic Leukemia | 1.6 | 97 | |
Brain and ONSd | 2.2 | 133 | |
Age 19 | All Sites | 27.5 | 1,651 |
Thyroid | 4.3 | 258 | |
Hodgkin Lymphoma | 4.0 | 238 | |
Testise | 3.4 | 204 | |
Leukemia | 2.9 | 174 | |
Acute Lymphocytic Leukemia | 1.2 | 70 | |
Brain and ONSd | 2.1 | 125 |
Footnotes:
a Rates are per 100,000 per year.
b Top 5 cancer sites were determined based on the 2011-2015 age-specific rate.
c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
d ONS = Other Nervous System. IBD = Intrahepatic Bile Duct.
e The rates for sex-specific cancer sites are calculated using the population for both sexes combined.
- Statistic not shown. Rate based on less than 16 cases for the time interval.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.